Search

Your search keyword '"Masitinib"' showing total 322 results

Search Constraints

Start Over You searched for: Descriptor "Masitinib" Remove constraint Descriptor: "Masitinib"
322 results on '"Masitinib"'

Search Results

1. Cromolyn sodium and masitinib combination inhibits fibroblast‐myofibroblast transition and exerts additive cell‐protective and antioxidant effects on a bleomycin‐induced in vitro fibrosis model.

2. Safety of masitinib in patients with neurodegenerative diseases: a meta-analysis of randomized controlled trials.

3. Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence.

4. Exploitation of Autophagy Inducers in the Management of Dementia: A Systematic Review.

5. A suitable drug structure for interaction with SARS‐CoV‐2 main protease between boceprevir, masitinib and rupintrivir; a molecular dynamics study

6. Masitinib Inhibits Hepatitis A Virus Replication.

7. Exploitation of Autophagy Inducers in the Management of Dementia: A Systematic Review

8. Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series

9. Masitinib analogues with the N-methylpiperazine group replaced – A new hope for the development of anti-COVID-19 drugs

10. Interaction of Masitinib with Organic Cation Transporters.

11. Evaluation of the therapeutic potential of masitinib and expression of its specific targets c‐Kit, PDGFR‐α, PDGFR‐β, and Lyn in canine prostate cancer cell lines.

13. Masitinib Inhibits Hepatitis A Virus Replication

14. The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS

15. Effects of tyrosine kinase inhibitor-masitinib mesylate on canine mammary tumour cell lines

16. Fullerenes against COVID-19: Repurposing C 60 and C 70 to Clog the Active Site of SARS-CoV-2 Protease.

17. Interaction of Masitinib with Organic Cation Transporters

18. The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS.

19. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis.

20. Amyotrophic lateral sclerosis: pathogenetic mechanisms and new approaches to pharmacotherapy (literature review)

21. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy.

22. Fullerenes against COVID-19: Repurposing C60 and C70 to Clog the Active Site of SARS-CoV-2 Protease

23. Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro

24. Characterization of in vivo metabolites in rat urine following an oral dose of masitinib by liquid chromatography tandem mass spectrometry

25. Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease.

26. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.

27. LC–MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate

28. A suitable drug structure for interaction with SARS‐CoV‐2 main protease between boceprevir, masitinib and rupintrivir; a molecular dynamics study.

29. A case of cutaneous mast cell tumor in a dog

30. Advances in Understanding and Treating Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review.

31. Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors.

32. LC-MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate.

33. IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.

34. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2

35. The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALS

36. In Silico Characterization of Masitinib Interaction with SARS‐CoV‐2 Main Protease

37. Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats

38. Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report

39. Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis

40. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?

41. Masitinib: The promising actor in the next season of the Amyotrophic Lateral Sclerosis treatment series.

42. A retrospective review of treatment and response of high-risk mast cell tumours in dogs.

43. Comparative Efficacy and Safety of Different Regimens of Advanced Gastrointestinal Stromal Tumors After Failure Prior Tyrosine Kinase Inhibitors: A Network Meta-Analysis

44. The VEGF inhibitor vatalanib regulates AD pathology in 5xFAD mice

45. LBA02-11 MASITINIB PLUS DOCETAXEL AS FIRST-LINE TREATMENT OF METASTATIC CASTRATE REFRACTORY PROSTATE CANCER: RESULTS FROM STUDY AB12003

46. Masitinib analogues with the N-methylpiperazine group replaced – A new hope for the development of anti-COVID-19 drugs.

47. Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for Multiple Sclerosis: A review.

48. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis.

49. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.

50. Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010‐2019)

Catalog

Books, media, physical & digital resources